FDA Approves L-GLUTAMINE — Renova Pharmaceuticals LLC

# FDA Approves Renova Pharmaceuticals' Generic L-Glutamine Oral Formulation Renova Pharmaceuticals LLC has received FDA approval for its generic L-glutamine oral formulation (ANDA219750), expanding the competitive landscape in the amino acid supplement market and potentially lowering costs for patients relying on glutamine for gastrointestinal and immune support. The approval positions Renova to capture market share in the growing oral glutamine segment, where increased generic competition typically accelerates price competition and broadens patient access.